Background
Phase III non-inferiority RCT (RTOG 1016), N=849 p16-positive (HPV-associated) oropharyngeal squamous cell carcinoma, stage III–IVB, eligible for definitive chemoradiotherapy. 182 North American institutions, enrolled 2011–2014. Stratified by T stage, N stage, ECOG PS, RT technique. Primary question: can cisplatin be replaced with cetuximab (less toxic) without sacrificing efficacy in HPV+ OPC?
Interventions and follow up
Arm A: Cetuximab (400 mg/m² loading, then 250 mg/m²/wk × 7 wk) + IMRT (70 Gy/35 fx)
Arm B: Cisplatin (100 mg/m² D1, D22) + IMRT (70 Gy/35 fx)
Primary endpoint: OS (non-inferiority; margin HR ≤1.45)
mFollow up: 4.5 yr
Arm B: Cisplatin (100 mg/m² D1, D22) + IMRT (70 Gy/35 fx)
Primary endpoint: OS (non-inferiority; margin HR ≤1.45)
mFollow up: 4.5 yr
Results
OS (5-yr): 77.9% (cetuximab) vs 84.6% (cisplatin), HR 1.45 (95% CI 1.04–2.05) — did NOT meet non-inferiority margin
PFS (5-yr): 67.7% vs 78.4%, HR 1.72 (95% CI 1.29–2.29) — cetuximab significantly inferior
LRC (5-yr): 87.9% vs 93.3%, HR 1.86 (95% CI 1.30–2.67)
PFS (5-yr): 67.7% vs 78.4%, HR 1.72 (95% CI 1.29–2.29) — cetuximab significantly inferior
LRC (5-yr): 87.9% vs 93.3%, HR 1.86 (95% CI 1.30–2.67)
Adverse events
Grade 3+ acute AEs: 77.4% (cetuximab) vs 84.8% (cisplatin)
Cisplatin arm: more nausea (7.1% vs 2.5%), hearing loss, renal toxicity
Cetuximab arm: more grade 3 acneiform rash 21.8%, mucositis 48.7%
Late dysphagia: comparable between arms
Cisplatin arm: more nausea (7.1% vs 2.5%), hearing loss, renal toxicity
Cetuximab arm: more grade 3 acneiform rash 21.8%, mucositis 48.7%
Late dysphagia: comparable between arms
Conclusions
Cetuximab + IMRT was inferior to cisplatin + IMRT for OS and PFS in HPV+ oropharyngeal SCC and failed to meet the non-inferiority threshold. Cisplatin-based CRT remains the standard of care; cetuximab should not replace cisplatin in HPV+ OPC in fit patients.
Key Limitations
Enrolled only p16+ OPC — results do not apply to HPV-negative disease. Cisplatin 100 mg/m² q3wk × 2 doses is a non-standard schedule; weekly cisplatin might differ in toxicity/equivalence. The chosen non-inferiority margin (HR 1.45) was generous. De-ESCALaTE showed identical findings with a different design, reinforcing the conclusion.
Clinical Context
RTOG 1016 definitively closed the door on cetuximab as a cisplatin substitute for fit patients with HPV+ OPC. ASCO/ESMO position cisplatin + IMRT as the preferred definitive regimen for LA HPV+ OPC; cetuximab + IMRT is acceptable only when cisplatin is contraindicated. Ongoing de-escalation strategies focus on RT dose reduction (not drug substitution) in favorable-risk patients.